Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 15/20 | 0.65 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
| ▸ | PDE6D | O43924 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5758646 | 0.92 | KIF11 (0.72) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL5791977 | 0.92 | KIF11 (0.73) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL5760697 | 0.88 | KIF11 (0.83) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL5758110 | 0.88 | KIF11 (0.64) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL5754805 | 0.86 | KIF11 (0.68) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL12386729 | 0.84 | KIF11 (0.68) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL5758258 | 0.84 | KIF11 (0.83) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL12386697 | 0.83 | KIF11 (0.79) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL12386717 | 0.81 | KIF11 (0.78) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL1892039 | 0.81 | KIF11 (0.78) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1689724-B1 | QUINAZOLINONE COMPOUNDS AS ANTICANCER AGENTS | NOVARTIS AG (CH) | 2011-12-21 | — | — | EP | disclosed |
| EP-1689724-A1 | QUINAZOLINONE COMPOUNDS AS ANTICANCER AGENTS | Chiron Corporation (US) | 2006-08-16 | — | — | EP | disclosed |
| US-20050209254-A1 | Quinazolinone compounds as anticancer agents | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2005-09-22 | — | — | US | disclosed |
| WO-2005051922-A1 | QUINAZOLINONE COMPOUNDS AS ANTICANCER AGENTS | CHIRON CORPORATION (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209254-A1 | Quinazolinone compounds as anticancer agents | TP53, NQO2, TOP1 | KIF11 2740/4885MAP1LC3B 1121/4885CYP3A4 404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.